Material and methods. Patients were divided into 3 groups according to the method of treatment: In the first group (n=32, BSA<10%) monotherapy with activated zinc pyrithione was performed, in the second one (n=27, BSA>10%) — combined application of topical activated zinc pyrithione and UV 311nm; in the third group — combined administration of activated zinc pyrithione and methotrexate. Results. Administration of activated zinc pyrithione in patients with limited psoriasis of various localization and regardless of the stage makes it possible to achieve significant positive results (decrease of PASI more than 75%) in most of the patients (87.5%). Administration of activated zinc pyrithione in combination with UV 311 nm or methotrexate in patients with spread psoriasis of various localization and regardless of the stage of the process are effective methods of treatment in the majority (88.9 and 82.9% respectively; PASI decrease of more than 75%) of patients. Conclusions. Monotherapy in limited forms of psoriasis and combined administration of topical drugs with activated zinc pyrithione and UV 311nm or methotrexate make it possible to achieve regression of clinical signs in the majority of patients, which significantly increases the quality of life of such category of patients.